Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Infectious disease antibodies bind viral envelope proteins or bacterial toxins for neutralization and infection studies. Sotrovimab, casirivimab and bamlanivimab bind the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Palivizumab and nirsevimab neutralize respiratory syncytial virus (RSV) by binding its fusion protein. Bezlotoxumab binds Clostridioides difficile toxin B, while raxibacumab and obiltoxaximab neutralize the protective antigen of anthrax toxin. Further antibodies target human immunodeficiency virus (HIV), influenza, hepatitis B virus and Ebola virus glycoproteins, as well as cytomegalovirus and BK virus.
Synonyms: CR57
Rafivirumab (CR57) is a monoclonal antibody designed for the prophylaxis of rabies, demonstrating neutralizing potency against a wide range of rabies virus (RABV) variants. This antibody is particularly useful in research focused on the development of therapeutic antibody cocktails targeting diverse strains of RABV.
Bezlotoxumab is a human monoclonal antibody that targets Clostridium difficile toxin B. By binding to this toxin, Bezlotoxumab effectively prevents the associated damage to intestinal epithelial cells and the onset of colitis. This antibody serves as a crucial tool in the study of gastrointestinal diseases and therapeutic interventions for C. difficile infections.
Synonyms: MAD-0004J08
Simaravibart (MAD-0004J08) is an IgG1κ monoclonal antibody specifically designed to target the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. This antibody binds with high specificity and affinity, making it an essential tool for research focused on the mechanisms of SARS-CoV-2 infection and immune response.
Synonyms: 514-G3
Omodenbamab is a human monoclonal antibody that targets Staphylococcal protein A (SpA), a critical component of the Staphylococcus aureus cell wall. With a dissociation constant (KD) of 0.0467 nM, this antibody demonstrates high affinity for SpA, effectively disrupting a major S. aureus immune evasion strategy. Omodenbamab is primarily utilized in the investigation of S. aureus bloodstream infections, providing a valuable tool for research in microbial pathogenesis and immune response mechanisms.
Synonyms: M777-16-3
Miromavimab (M777-16-3) is a monoclonal antibody specifically targeting the ectodomain epitope G-II of the rabies virus strain ERAGP. This antibody is designed for precise binding and neutralization of the rabies virus, making it an essential tool for research in virology and infectious diseases.
Synonyms: KIND-030
Anivovetmab (KIND-030) is a monoclonal antibody of the IgG2 subtype, specifically targeting the VP2 protein, a major capsid protein of the canine parvovirus. This antibody is designed for the investigation of canine parvovirus infections, providing a critical tool for research into the pathogenesis and immune response to this virus. Anivovetmab is instrumental in advancing our understanding of viral mechanisms and potential therapeutic interventions for canine parvovirus.
Synonyms: INH-H 2002
Tefibazumab is a humanized IgG1κ monoclonal antibody specifically designed to target and bind to clumping factor A, a surface-expressed adhesion protein. This antibody is utilized primarily in the study of serious infections caused by Staphylococcus aureus, offering a valuable tool for research in microbial pathogenesis and immune response mechanisms.
Synonyms: CT-P22; CT120
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA). This antibody demonstrates a broad neutralizing capacity against multiple subtypes including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. In vivo studies have confirmed Firivumab's protective efficacy against the H1N1 virus in murine models, highlighting its potential for therapeutic applications in influenza A virus infections.
Synonyms: CR6261
Diridavumab is a monoclonal antibody targeting the HA stalk of the influenza virus. It functions by stabilizing the prefusion conformation of hemagglutinin (HA) and inhibiting the pH-dependent fusion of cellular and viral membranes within endosomes. This antibody is specifically utilized in research focused on the H2 subtype of the influenza virus, providing a valuable tool for studies aimed at understanding viral entry mechanisms and developing therapeutic strategies.
Synonyms: ETI 204
Obiltoxaximab (ETI 204) is a highly potent monoclonal antibody targeting the protective antigen (PA) component of Bacillus anthracis, the bacterium responsible for anthrax. This antibody is critical in disrupting the assembly of anthrax toxin, thereby preventing the intoxication of target cells. Demonstrating efficacy in animal models, Obiltoxaximab enhances survival rates and impedes the peripheral dissemination of the bacteria. It is primarily utilized in research focused on inhalational anthrax, as well as associated bacteremia and toxemia. This makes Obiltoxaximab an essential tool for studies aimed at understanding and mitigating the pathogenic mechanisms of anthrax.
Libevitug is a human monoclonal antibody of the IgG1λ2 subtype designed to target Hepatitis B virus (HBV). For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control.
Synonyms: BMS 4182137; VIR 7832
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody designed to specifically target the spike glycoprotein of SARS-CoV-2. This antibody exhibits high affinity binding to the receptor-binding domain (RBD) of the recombinant spike protein, demonstrated by an equilibrium dissociation constant (Kd) of 0.21 nM and an effective concentration (EC50) of 14.9 ng/mL. These properties suggest that Beludavimab is highly effective in binding to the spike protein, potentially inhibiting the virus's ability to enter host cells and proliferate. This antibody is a valuable tool for research focused on the mechanisms of SARS-CoV-2 infection and the development of therapeutic strategies.
Synonyms: SCTA01
Upanovimab (SCTA01) is a monoclonal antibody specifically designed to target the spike (S) protein of SARS-CoV-2. This antibody binds with high specificity and affinity to the S protein, potentially neutralizing the virus and preventing its entry into host cells. Upanovimab is utilized in research focused on the therapeutic and prophylactic potential against COVID-19.
Synonyms: AZD3152
Sipavibart is a human IgG1 λ2 monoclonal antibody targeting SARS-CoV-2. For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control.
Synonyms: LY-3853113; LY-COV1404
Bebtelovimab is a humanized IgG1-λ2 monoclonal antibody specifically designed to target SARS-CoV-2, the virus responsible for COVID-19. This antibody demonstrates potent neutralizing activity against various SARS-CoV-2 variants, providing mild-to-moderate efficacy in inhibiting the progression of COVID-19. Bebtelovimab is engineered for precise binding to the spike protein of the virus, disrupting its ability to infect host cells. This makes it a valuable tool for research into viral pathogenesis and the development of therapeutic strategies against COVID-19.
Synonyms: ZRC3308-B10
Nepuvibart (ZRC3308-B10) is a monoclonal antibody of the IgG1 subtype, designed specifically to target SARS-CoV-2. It exhibits high binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Nepuvibart can be administered in conjunction with ZRC3308-A7 in a 1:1 ratio. This combination has been shown to be effective in the prevention of COVID-19, as well as in the treatment of the early stages of the disease prior to the onset of severe symptoms.
Synonyms: KD-247
Suvizumab (KD-247) is a neutralizing monoclonal antibody targeting HIV-1. Demonstrating potent efficacy, Suvizumab effectively neutralizes diverse HIV-1 strains including HIV-1MN, HIV-1SF2, and HIV-189.6, with respective IC50 values of 0.1 µg/mL, 1.0 µg/mL, and 0.2 µg/mL. This antibody has been shown to significantly reduce viral load, offering a promising therapeutic option for the management of HIV infection. Suvizumab is well-tolerated and holds potential for both therapeutic and prophylactic applications in HIV management.
Synonyms: MEDI3902
Gremubamab (MEDI3902) is a humanized IgG1 kappa monoclonal antibody designed to target both the PcrV protein and Psl exopolysaccharide on Pseudomonas aeruginosa. By binding to these specific antigens, Gremubamab offers a dual-action approach in the study of Pseudomonas aeruginosa infections, making it a valuable tool for research in microbial pathogenesis and immune response mechanisms.
Silevimig is a monoclonal antibody specifically targeting the rabies virus (RABV). This antibody binds to the viral surface proteins, neutralizing the virus and preventing its propagation. Silevimig is utilized extensively in research focusing on the development of rabies treatments and vaccines, and in studies exploring the pathophysiology of this virus.
Synonyms: BRII-196
Amubarvimab (BRII-196) is a human IgG1 monoclonal antibody designed to target distinct, non-competing epitopes on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It exhibits a binding affinity with a dissociation constant (K_D) of 5.88 nM, demonstrating potent neutralization capabilities against various SARS-CoV-2 variants. This specificity and efficacy make Amubarvimab a valuable tool for research into the mechanisms of viral entry and immune evasion.
Synonyms: CTB012
Mazorelvimab (CTB012) is a humanized IgG1κ monoclonal antibody designed to target the rabies virus (RABV) by binding to non-overlapping epitopes on the RABV glycoprotein. This antibody specifically interacts with highly discontinuous, conserved residues that are distinct from antigenic site III, ensuring unique specificity. Mazorelvimab is primarily investigated for its potential use in the prevention of rabies, offering a promising therapeutic approach in rabies prophylaxis.
Ibramvibart is a human IgG1 κ monoclonal antibody targeting the Spike protein of SARS-CoV-2. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.
Synonyms: CB 6; JS016
Etesevimab (JS016) is a recombinant, fully human, neutralizing monoclonal antibody of the IgG1 subclass, specifically targeting the SARS-CoV-2 virus. This antibody binds with high specificity to the spike protein of SARS-CoV-2, thereby inhibiting the virus's ability to enter host cells and propagate infection. Etesevimab is utilized in research focused on the therapeutic response and viral mechanism of SARS-CoV-2.
Pemivibart is a human IgG1 λ2 monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental controls, it is recommended to use Human IgG1 lambda2 Isotype Control.
Synonyms: REGN10933
Casirivimab (REGN10933) is a human monoclonal antibody designed to specifically target the SARS-CoV-2 virus, responsible for COVID-19. This antibody has shown limitations in its efficacy against emerging COVID-19 variants. For enhanced therapeutic potential, Casirivimab can be administered in conjunction with Imdevimab. This combination has been demonstrated to modify the pulmonary response in K18-hACE2 transgenic mice infected with the SARS-CoV-2 δ variant, leading to a significant reduction in viral load and amelioration of clinical symptoms.
